<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34834437</PMID><DateRevised><Year>2021</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4426</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of personalized medicine</Title><ISOAbbreviation>J Pers Med</ISOAbbreviation></Journal><ArticleTitle>Vaccinated Patients Admitted in ICU with Severe Pneumonia Due to SARS-CoV-2: A Multicenter Pilot Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1086</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jpm11111086</ELocationID><Abstract><AbstractText><b>Background:</b> The aim of this study was to analyze the percentage of patients admitted to the ICU having received the vaccine against COVID-19, to describe the clinical profile of vaccinated patients admitted to the ICU, and to assess the humoral immune response to vaccination. <b>Methods:</b> In this multicenter prospective descriptive cohort study, consecutive critically ill patients with confirmed SARS-CoV-2 pneumonia who received at least one dose of the SARS-CoV-2 vaccine were included. The time of study was from 1 July to 10 August of 2021. <b>Results:</b> Of the 94 consecutive patients from seven Andalusian ICUs admitted during the time of study, 50 (53.2%) received at least one dose of anti SARS-CoV-2 vaccine. No patient was admitted having previously had SARS-CoV-2 infection. The B.1.617.2 (Delta) variant was the most frequently identified, in 80.76% of cases. Patients with a complete vaccination with non-optimal antibody levels were immunocompromised. Fifteen patients were admitted to the ICU with Acute Respiratory Distress Syndrome (ARDS) without having completed their vaccination; the clinical profile was younger and with less comorbidities compared to patients with full vaccination. There were no differences in severity of ARDS. <b>Conclusions:</b> Most of the patients who were admitted to the ICU having received a dose of the vaccine were not optimally vaccinated; fully vaccinated patients who did not obtain optimal serum antibody levels were patients considered immunocompromised.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Estella</LastName><ForeName>Ángel</ForeName><Initials>Á</Initials><Identifier Source="ORCID">0000-0003-0665-557X</Identifier><AffiliationInfo><Affiliation>Intensive Care Unit, Medicine Department University of Cadiz, University Hospital of Jerez, INiBICA, 11001 Jerez, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantón</LastName><ForeName>Mª Luisa</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0003-1024-2954</Identifier><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital Virgen Macarena, 41013 Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muñoz</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Hospital Costa del Sol de Marbella, 29001 Málaga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higueras</LastName><ForeName>Isabel Rodriguez</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital Torrecárdenas, 04001 Almería, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recuerda Núñez</LastName><ForeName>María</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8466-9307</Identifier><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital of Jerez, INiBICA, 11001 Jerez, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tejero Aranguren</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6303-852X</Identifier><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital San Cecilio, 18001 Granada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaya</LastName><ForeName>Benito</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Hospital Costa del Sol de Marbella, 29001 Málaga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gómez</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Hospital Costa del Sol de Marbella, 29001 Málaga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amaya</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital Virgen del Rocío, 41013 Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurtado Martinez</LastName><ForeName>Ángela</ForeName><Initials>Á</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital Virgen de Valme, 41013 Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Valle Odero Bernal</LastName><ForeName>María</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital of Jerez, INiBICA, 11001 Jerez, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De la Fuente</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital Reina Sofía, 14004 Córdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alados</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital of Jerez, INiBICA, 11001 Jerez, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garnacho-Montero</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital Virgen Macarena, 41013 Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>On Behalf Of The Group Of Infectious Diseases Of The Andalusian Society Of Intensive Care And Coronary Units Samiuc</LastName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Pers Med</MedlineTA><NlmUniqueID>101602269</NlmUniqueID><ISSNLinking>2075-4426</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Delta variant SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">severe pneumonia</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34834437</ArticleId><ArticleId IdType="pii">jpm11111086</ArticleId><ArticleId IdType="doi">10.3390/jpm11111086</ArticleId><ArticleId IdType="pmc">PMC8625038</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nat Med. 2021 Aug;27(8):1370-1378</Citation><ArticleIdList><ArticleId IdType="pubmed">34108716</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Immunol. 2021 Jun 15;6(60):</Citation><ArticleIdList><ArticleId IdType="pubmed">34131023</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2021 Aug 17;12(1):5061</Citation><ArticleIdList><ArticleId IdType="pubmed">34404775</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2021 Oct;80(10):1322-1329</Citation><ArticleIdList><ArticleId IdType="pubmed">34362747</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Nov 21;396(10263):1614-1616</Citation><ArticleIdList><ArticleId IdType="pubmed">33159850</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Res. 2021 Dec;69(6):576-583</Citation><ArticleIdList><ArticleId IdType="pubmed">34417958</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2021 Jun 18;59(7):e0038821</Citation><ArticleIdList><ArticleId IdType="pubmed">33827901</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2021 Apr 15;184(8):2201-2211.e7</Citation><ArticleIdList><ArticleId IdType="pubmed">33743891</ArticleId></ArticleIdList></Reference><Reference><Citation>Med J Aust. 2020 Jul;213(2):54-56.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">32572965</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2021 Aug 12;385(7):585-594</Citation><ArticleIdList><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Intensiva (Engl Ed). 2021 Mar 8;:</Citation><ArticleIdList><ArticleId IdType="pubmed">33812670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2021 Mar 6;397(10277):881-891</Citation><ArticleIdList><ArticleId IdType="pubmed">33617777</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Drug Deliv Rev. 2021 May;172:314-338</Citation><ArticleIdList><ArticleId IdType="pubmed">33482248</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Disord Drug Targets. 2021 Jul 20;:</Citation><ArticleIdList><ArticleId IdType="pubmed">34303332</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2021 Jun 11;70(23):858-864</Citation><ArticleIdList><ArticleId IdType="pubmed">34111059</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2021 Oct 14;385(16):1474-1484</Citation><ArticleIdList><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>